Analyse the evolution of drug scheduling in India from Schedule H to Schedule H2. How does the QR-code mandate balance patient safety with compliance costs for small manufacturers?

Q. Analyse the evolution of drug scheduling in India from Schedule H to Schedule H2. How does the QR-code mandate balance patient safety with compliance costs for small manufacturers? (15 marks, 250 words)

India's drug-scheduling regime under the Drugs and Cosmetics Act, 1940 has evolved from access control toward digital traceability, culminating in the June 2026 expansion of Schedule H2 to vaccines, antimicrobials, NDPS drugs and anti-cancer medicines [1]. This marks a shift from prescription discipline to supply-chain integrity.

Evolution of drug scheduling - Schedule H: restricted specified drugs to prescription-only sale — the baseline access safeguard. - Schedule H1 (2013): added mandatory record-keeping for habit-forming drugs and higher antibiotics, targeting irrational use and antimicrobial resistance. - Schedule H2 (from 2022): introduced QR/bar-code authentication, first for APIs (G.S.R. 20(E)), then top 300 brands via G.S.R. 823(E), effective 1 August 2023 [2]. - 2026 expansion: high-risk categories added, enabling manufacturer-to-patient tracing [1].

Balancing patient safety and compliance cost - Safety gains: unit-level QR codes curb spurious vaccines and fake oncology drugs, enable rapid batch recall, and support AMR containment — code data is smartphone-readable for patient-end verification [1]. - Cost concerns: serialisation, printing and IT integration burden small manufacturers. - Balancing measures: phased rollout (APIs → brands → high-risk categories) and staggered enforcement — antimicrobials only from 2028 — cushion adjustment [1]. Placement on secondary labels where space is short reduces redesign cost [2].

The framework achieves calibrated regulation: prioritising high-risk drugs first while sequencing obligations. Pairing it with reader infrastructure for rural chemists would advance the Right to Health under Article 21 and align with WHO anti-counterfeiting goals.

(~250 words)

Sources: 1. Union Health Ministry Expands QR Code-Based Drug Traceability Framework to Vaccines, Antimicrobials and Anti-Cancer Medicines — PIB/MoHFW (2026) — Schedule H2 expansion, phased enforcement (antimicrobials from 2028), patient-end authentication 2. Drugs Rules, 1945 — G.S.R. 823(E) QR-code notification for top 300 brands (in force 1 August 2023) — PIB/MoHFW — earlier Schedule H2 rollout and label-placement rule